Development process and clinic applications of antibody

QU Yi; LI Zhiyong; MIAO Chaoyu

doi:10.3969/j.issn.1006-0111.2017.04.004

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Monoclonal antibodies have become an important part of biotechnology and pharmaceutical industry. Currently chimeric antibody, humanized antibody and fully human antibody are generally prepared by genetic engineering. With constant improvement in the antibody preparation technology, the antibody applications are rapidly increasing, especially in the development of antibody medications. In recent years, there have been many significant antibody drugs (such as PD-1 antibody, IL-17 antibody, IL-5 antibody, PCSK9 antibody) for the treatment of various diseases and solved a number of clinical problems. In modern medicine, monoclonal antibodies have become effective diagnostic and therapeutic tools. This article is a brief review of the recent antibody development process, clinic applications and significant antibody drugs approved by FDA.

Development process and clinic applications of antibody

Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2016-10-27

Rev Recd Date: 2017-02-20

Key words:

Abstract: Monoclonal antibodies have become an important part of biotechnology and pharmaceutical industry. Currently chimeric antibody, humanized antibody and fully human antibody are generally prepared by genetic engineering. With constant improvement in the antibody preparation technology, the antibody applications are rapidly increasing, especially in the development of antibody medications. In recent years, there have been many significant antibody drugs (such as PD-1 antibody, IL-17 antibody, IL-5 antibody, PCSK9 antibody) for the treatment of various diseases and solved a number of clinical problems. In modern medicine, monoclonal antibodies have become effective diagnostic and therapeutic tools. This article is a brief review of the recent antibody development process, clinic applications and significant antibody drugs approved by FDA.

HTML

Reference (16)

[1]	Dixit R, Herz J, Dalton R, et al. Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens[J]. Vaccine, 2016, 34(9):1152-1161.
[2]	Gaughan CL. The present state of the art in expression, production and characterization of monoclonal antibodies[J]. Mol Divers, 2016, 20(1):255-270.
[3]	Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms[J]. Curr Opin Immunol, 2008, 20(4):450-459.
[4]	Bruggemann M, Osborn MJ, Ma B, et al. Human antibody production in transgenic animals[J]. Arch Immunol Ther Exp (Warsz), 2015, 63(2):101-108.
[5]	de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches[J]. Curr Opin Immunol, 2016, 40:14-23.
[6]	Yamada T. Therapeutic monoclonal antibodies[J]. Keio J Med, 2011, 60(2):37-46.
[7]	Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016, 45:7-18.
[8]	Fala L. Cosentyx (Secukinumab): First IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis[J]. Am Health Drug Benefits, 2016, 9(Spec Feature):60-63.
[9]	Maselli DJ, Velez MI, Rogers L. Reslizumab in the management of poorly controlled asthma: the data so far[J]. J Asthma Allergy, 2016, 9:155-162.
[10]	Lim BN, Tye GJ, Choong YS, et al. Principles and application of antibody libraries for infectious diseases[J]. Biotechnol Lett, 2014, 36(12):2381-2392.
[11]	Uchtenhagen H, Schiffner T, Bowles E, et al. Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein[J]. J Immunol, 2014, 192(12):5802-5812.
[12]	Pleass RJ, Holder AA. Opinion: antibody-based therapies for malaria[J]. Nat Rev Microbiol, 2005, 3(11):893-899.
[13]	Balu S, Reljic R, Lewis MJ, et al. A novel human IgA monoclonal antibody protects against tuberculosis[J]. J Immunol, 2011, 186(5):3113-3119.
[14]	Chapman MJ, Stock JK, Ginsberg HN. PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era[J]. Curr Opin Lipidol, 2015, 26(6):511-520.
[15]	Freskgard PO, Urich E. Antibody therapies in CNS diseases[J]. Neuropharmacology, 2016,DOI: 10.1016/j.neuropharm.2016.03.014.
[16]	Cohan S. Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis[J]. Biologics, 2016, 10:119-138.

Message Board

Development process and clinic applications of antibody

doi: 10.3969/j.issn.1006-0111.2017.04.004

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views